Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (33)
  • Open Access


    Managing the Adult Congenital Heart Disease Patient in the COVID-19 Pandemic—A New York Perspective

    Jodi L. Feinberg1, Frank Cecchin1,2, Arianna Gonzalez1, Emily Johnson2, Dan G. Halpern1,*

    Congenital Heart Disease, Vol.15, No.3, pp. 141-146, 2020, DOI:10.32604/CHD.2020.012039

    Abstract Adults with congenital heart disease (ACHD) are likely at increased risk for complications of COVID-19. ACHD centers should prepare to deliver routine cardiac care and support for patients with COVID-19 safely at home, as the number of COVID-19 infections worldwide continues to increase. This brief report aims to share the strategies we have used in our ACHD program to manage and treat our patients during this global health crisis at one of the initial epicenters of the pandemic in New York City, and offer suggestions for preparation for ACHD clinicians. More >

  • Open Access


    Plant Derived Antiviral Products for Potential Treatment of COVID-19: A Review

    Rashid Iqbal Khan1,*, Mazhar Abbas1, Khurram Goraya2, Muhammad Zafar-ul-Hye3, Subhan Danish3

    Phyton-International Journal of Experimental Botany, Vol.89, No.3, pp. 438-452, 2020, DOI:10.32604/phyton.2020.010972

    Abstract COVID-19 caused by SARS-CoV-2 is declared global pandemic. The virus owing high resemblance with SARS-CoV and MERS-CoV has been placed in family of beta-coronavirus. However, transmission and infectivity rate of COVID-19 is quite higher as compared to other members of family. Effective management strategy with potential drug availability will break the virus transmission chain subsequently reduce the pressure on the healthcare system. Extensive research trials are underway to develop novel efficient therapeutics against SARS-CoV-2. In this review, we have discussed the origin and family of coronavirus, structure, genome and pathogenesis of virus SARS-CoV-2 inside human host cell; comparison among SARS,… More >

  • Open Access


    Updated thoughts on SARS-CoV-2 and coronavirus therapies, fighting and surviving


    BIOCELL, Vol.44, No.2, pp. 127-135, 2020, DOI:10.32604/biocell.2020.010018

    Abstract From late December 2019 a new human-adapted coronavirus, SARS-CoV-2, was observed and isolated in clustered patients in Wuhan, China. It has been proved to be able to transmit human-to-human and cause pneumonia, leading to about 2% fatality. Its genome characteristics, immune responses and related potential treatments, such as chemical drugs, serum transfusion and vaccines including DNA vaccines, are discussed in this review for a brief summary. More >

Displaying 31-40 on page 4 of 33. Per Page